Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

The protein-based vaccine now covers the LP.8.1 variant and can be given to adolescents aged 12 years or older who previously received mRNA vaccines.

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups ...

Alveolar bone, the specialized tissue within the jawbone, plays an important role in periodontal health. This tissue has a ...

Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable ...

Dr. Park Ji-sun (co-first author), and a joint research team of researchers Lee Ye-eun (co-first author) proposed a new ...

Following a diagnosis, a Pennsylvania woman underwent genetic testing that revealed she had a very rare, inherited form of ...

In what could prove to be a major breakthrough for cancer patients, an mRNA-based vaccine has been developed, demonstrating 100% efficacy and safety in clinical trials.

A little less than a year after targeting Moderna in an mRNA vaccine patent lawsuit, GSK is widening the scope of its litigation by throwing its rival’s next-generation COVID-19 shot into the fold. In ...

Deborah Fuller receives funding from the National Institutes of Health. She is co-founder and a scientific advisor for two biotech companies developing nucleic acid vaccine technologies that are not ...

Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their ...

Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their ...